Biohaven Ltd. Cash Acquired from Acquisition
Biohaven Ltd. (BHVN) reported Cash Acquired from Acquisition of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Cash
us-gaap:CashAcquiredFromAcquisition · last filed 2026-03-02
- Biohaven Ltd. cash acquired from acquisition for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Biohaven Ltd. cash acquired from acquisition for the quarter ending 2024-12-31 was $0.00.
- Biohaven Ltd. cash acquired from acquisition for the quarter ending 2024-09-30 was $0.00.
- Biohaven Ltd. cash acquired from acquisition for the quarter ending 2024-06-30 was $0.00.
- Biohaven Ltd. cash acquired from acquisition for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Biohaven Ltd. cash acquired from acquisition for fiscal 2024 was $391.00K.
- Biohaven Ltd. cash acquired from acquisition for fiscal 2023 was $0.00.
- Biohaven Ltd. cash acquired from acquisition for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Cash Acquired from Acquisition 3 month | Cash Acquired from Acquisition 6 month | Cash Acquired from Acquisition 9 month | Cash Acquired from Acquisition 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $391.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $391.00K 10-Q · filed 2024-11-12 | $391.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $391.00K 10-Q · filed 2024-08-09 | $391.00K derived: sum of 3 quarters · filed 2026-03-02 | $391.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $391.00K 10-Q · filed 2025-05-12 | $391.00K derived: sum of 2 quarters · filed 2026-03-02 | $391.00K derived: sum of 3 quarters · filed 2026-03-02 | $391.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | $0.00 derived: sum of 3 quarters · filed 2025-03-03 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.88M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $1.88M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |